Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.63 |
| ▸ | IKZF2 | Q9UKS7 | 9/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.52 |
| ▸ | SALL4 | Q9UJQ4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31726960 | 0.93 | CRBN (0.73) | CRBNIKZF2DDB1CSNK1A1SALL4 | |
| SCHEMBL27305814 | 0.93 | CRBN (0.73) | CRBNIKZF2DDB1CSNK1A1SALL4 | |
| SCHEMBL4449425 | 0.93 | CRBN (0.73) | CRBNIKZF2DDB1CSNK1A1SALL4 | |
| SCHEMBL29614623 | 0.93 | CRBN (0.73) | CRBNIKZF2DDB1CSNK1A1SALL4 | |
| SCHEMBL22639152 | 0.85 | CRBN (0.86) | CRBNIKZF2DDB1CSNK1A1 | |
| SCHEMBL18270982 | 0.85 | CRBN (0.86) | CRBNIKZF2DDB1CSNK1A1 | |
| SCHEMBL18270971 | 0.85 | CRBN (0.63) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL19100445 | 0.83 | CRBN (0.61) | CRBNIKZF2DDB1CSNK1A1SALL4 | |
| SCHEMBL30984806 | 0.83 | CRBN (0.67) | CRBNIKZF2DDB1CSNK1A1SALL4 | |
| SCHEMBL19792875 | 0.83 | CRBN (0.57) | CRBNIKZF2DDB1CSNK1A1SALL4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612140-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | Captor Therapeutics S.A. (PL) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024094819-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2024-05-10 | — | — | WO | disclosed |